Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time to HIV seroconversion after needlestick injury.
Meyohas MC, Morand-Joubert L, Van de Wiel P, Mariotti M, Lefrère JJ. Meyohas MC, et al. Lancet. 1995 Jun 24;345(8965):1634-5. doi: 10.1016/s0140-6736(95)90139-6. Lancet. 1995. PMID: 7783549 No abstract available.
Viral load in symptomatic primary HIV-infection.
Joubert L, Meyohas MC, Ollivier I, Frottier J, Petit JC, Mariotti M, Lefrère JJ. Joubert L, et al. Among authors: meyohas mc. AIDS. 1993 Aug;7(8):1127-8. doi: 10.1097/00002030-199308000-00018. AIDS. 1993. PMID: 8397953 No abstract available.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.
Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, Lefebvre B, Allavena C, Katlama C, Yazdanpanah Y, Molina JM, Petrov-Sanchez V, Gibowski S, Alvarez JC, Leibowitch J, Capeau J, Fellahi S, Duracinsky M, Morand-Joubert L, Costagliola D, Alvarez JC, Girard PM; ANRS 170 QUATUOR study group. Landman R, et al. Lancet HIV. 2022 Feb;9(2):e79-e90. doi: 10.1016/S2352-3018(21)00300-3. Lancet HIV. 2022. PMID: 35120640 Clinical Trial.
AIDS vaccine therapy: phase I trial.
Picard O, Giral P, Defer MC, Fouchard M, Morel M, Meyohas MC, Lebas J, Imbert JC, Frottier J, Salaun JJ, et al. Picard O, et al. Among authors: meyohas mc. Lancet. 1990 Jul 21;336(8708):179. doi: 10.1016/0140-6736(90)91699-b. Lancet. 1990. PMID: 1973493 Clinical Trial. No abstract available.
Correlation between HIV provirus burden and in utero transmission.
Roques P, Marce D, Courpotin C, Mathieu FP, Herve F, Boussin FD, Narwa R, Meyohas MC, Dollfus C, Dormont D. Roques P, et al. Among authors: meyohas mc. AIDS. 1993 Nov;7 Suppl 2:S39-43. doi: 10.1097/00002030-199311002-00009. AIDS. 1993. PMID: 7909225
165 results